PRED-G
LOE ApproachingNDAOPHTHALMICSUSPENSION/DROPS
Approved
Jun 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRED-G is an ophthalmic suspension approved in 1988 for eye conditions; the specific indication and mechanism of action are not publicly detailed in available data. As a small-molecule drop formulation, it targets localized ocular pathology.
LOE Approaching
Long-established product nearing loss of exclusivity; commercial teams likely focused on lifecycle management and transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PRED-G offers experience in mature-product management and LOE strategy within a stable, established brand under AbbVie's portfolio. Career growth will center on lifecycle extension, pricing defense, and managed markets rather than innovation-focused roles.
Brand ManagerField Sales Representative
Worked on PRED-G at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.